α-pyrone derivatives from the endophytic Fusarium sp. L33 isolated from Dioscorea opposita

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2024-06-18 DOI:10.1016/j.phytol.2024.06.002

Ruo-Dan Tian , Meng-Ke Sheng , Ying-Fei Zhao , Chun-Nan Wen , Miao Liu , Bing-Ji Ma

引用次数: 0

Abstract

Two new α-pyrone derivatives, fusaripyrones C and D (1 and 2), along with six known compounds, namely phomapyrone C (3), fusarilactone A (4), pleospyrone D (5), 5-hydroxy-7-(2′-hydroxypropyl)-2-methyl-chromone (6), phenylacetic acid (7), and p-hydroxyphenylacetic acid (8) were isolated from Fusarium sp. L33, an endophytic fungus isolated from the leaves of Dioscorea opposita. Their structures were elucidated by NMR spectra, HRESIMS, optical rotation experiments and single-crystal X-ray diffraction analysis. Compounds 2, 3, and 6 were evaluated for their cytotoxic activity against five selected human tumor cell lines.

查看原文本刊更多论文

从薯蓣中分离出的内生镰刀菌 L33 的 α-吡喃酮衍生物

从从薯蓣叶中分离出的内生真菌 Fusarium sp. L33 中分离出了两种新的α-吡喃酮衍生物 fusaripyrones C 和 D（1 和 2），以及六种已知化合物，即 phomapyrone C（3）、fusarilactone A（4）、pleospyrone D（5）、5-羟基-7-(2′-羟基丙基)-2-甲基-Chromone（6）、苯乙酸（7）和对羟基苯乙酸（8）。L33 中分离出来。通过核磁共振波谱、HRESIMS、光学旋转实验和单晶 X 射线衍射分析阐明了它们的结构。评估了化合物 2、3 和 6 对五种选定的人类肿瘤细胞系的细胞毒活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.